Evidence map›Paper›PMID 29973576›Full record

ArticleMolecules (Basel, Switzerland)2018

Genistein Improves Skin Flap Viability in Rats: A Preliminary In Vivo and In Vitro Investigation.

Lenka Fáber, Ivan Kováč, Petra Mitrengová, Martin Novotný, Lenka Varinská, Tomáš Vasilenko, Martin Kello, Matúš Čoma, Tomáš Kuruc, Klaudia Petrová and 12 more

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 2 institutions in 1 country.

Lenka FáberDepartment of Pharmacology, Faculty of Medicine, Pavol Jozef Šafárik University, 040 11 Košice, Slovak Republic. lenka.faber@yahoo.com.
Ivan KováčDepartment of Biomedical Research, East-Slovak Institute of Cardiovascular Diseases, 040 11 Košice, Slovak Republic. ivankovac.kovi@gmail.com.
Petra MitrengováDepartment of Pharmacognosy and Botany, Comenius University, Faculty of Pharmacy, 832 32 Bratislava, Slovak Republic. peta.mitrengova@fpharm.uniba.sk.
Martin NovotnýDepartment of Biomedical Research, East-Slovak Institute of Cardiovascular Diseases, 040 11 Košice, Slovak Republic. nagy@fpharm.uniba.sk.
Lenka VarinskáDepartment of Pharmacology, Faculty of Medicine, Pavol Jozef Šafárik University, 040 11 Košice, Slovak Republic. lenkavarinska@yahoo.com.
Tomáš VasilenkoDepartment of Biomedical Research, East-Slovak Institute of Cardiovascular Diseases, 040 11 Košice, Slovak Republic. tomasvasilenko@gmail.com.
Martin KelloDepartment of Pharmacology, Faculty of Medicine, Pavol Jozef Šafárik University, 040 11 Košice, Slovak Republic. kellomartin@yahoo.com.ORCID 0000-0002-2454-5799
Matúš ČomaDepartment of Pharmacology, Faculty of Medicine, Pavol Jozef Šafárik University, 040 11 Košice, Slovak Republic. coma.matus@gmail.com.
Tomáš KurucDepartment of Pharmacology, Faculty of Medicine, Pavol Jozef Šafárik University, 040 11 Košice, Slovak Republic. tomaskuruc@centrum.sk.
Klaudia PetrováDepartment of Pharmacology, Faculty of Medicine, Pavol Jozef Šafárik University, 040 11 Košice, Slovak Republic. claudy.petrova@gmail.com.
Ivana MiláčkováDepartment of Pharmacognosy and Botany, Comenius University, Faculty of Pharmacy, 832 32 Bratislava, Slovak Republic. imilackova@gmail.com.
Anika KuczmannováDepartment of Pharmacognosy and Botany, Comenius University, Faculty of Pharmacy, 832 32 Bratislava, Slovak Republic. kuczmannova@fpharm.uniba.sk.
Vlasta PeržeľováDepartment of Biomedical Research, East-Slovak Institute of Cardiovascular Diseases, 040 11 Košice, Slovak Republic. vlasta.perzelova@gmail.com.
Štefánia MižákováClinic of Heart Surgery, East-Slovak Institute of Cardiovascular Diseases and Pavol Jozef Šafárik University, 040 11 Košice, Slovak Republic. smizakova@vusch.sk.
Erik Dosedlast Private Hospital Košice-Šaca and Pavol Jozef Šafárik University, 040 15 Košice, Slovak Republic. edosedla@gmail.com.
František SabolClinic of Heart Surgery, East-Slovak Institute of Cardiovascular Diseases and Pavol Jozef Šafárik University, 040 11 Košice, Slovak Republic. fsabol@vusch.sk.
Ján LuczyClinic of Heart Surgery, East-Slovak Institute of Cardiovascular Diseases and Pavol Jozef Šafárik University, 040 11 Košice, Slovak Republic. jluczy@vusch.sk.
Milan NagyDepartment of Pharmacognosy and Botany, Comenius University, Faculty of Pharmacy, 832 32 Bratislava, Slovak Republic. nagy@fpharm.uniba.sk.
Jaroslav MajerníkDepartment of Medical Informatics, Faculty of Medicine, Pavol Jozef Šafárik University, 040 11 Košice, Slovak Republic. jaroslav.majernik@upjs.sk.ORCID 0000-0003-1942-0497
Martin KoščoClinic of Angiology, East-Slovak Institute of Cardiovascular Diseases and Pavol Jozef Šafárik University, 04011 Košice, Slovak Republic. mkosco@vusch.sk.
Pavel MučajiDepartment of Pharmacognosy and Botany, Comenius University, Faculty of Pharmacy, 832 32 Bratislava, Slovak Republic. mucaji@fpharm.uniba.sk.
Peter GálDepartment of Pharmacology, Faculty of Medicine, Pavol Jozef Šafárik University, 040 11 Košice, Slovak Republic. pgal@vusch.sk.ORCID 0000-0002-3398-3408
University of Pavol Jozef Šafárik · SKComenius University Bratislava · SK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Selective estrogen receptor modulators (SERMs) have been developed to achieve beneficial effects of estrogens while minimizing their side effects. In this context, we decided to evaluate the protective effect of genistein, a natural SERM, on skin flap viability in rats and in a series of in vitro experiments on endothelial cells (migration, proliferation, antioxidant properties, and gene expression profiling following genistein treatment). Our results showed that administration of genistein increased skin flap viability, but importantly, the difference is only significant when treatment is started 3 days prior the flap surgery. Based on our in vitro experiments, it may be hypothesized that the underlying mechanism may rather by mediated by increasing SOD activity and Bcl-2 expression. The gene expression profiling further revealed 9 up-regulated genes (angiogenesis/inflammation promoting: CTGF, CXCL5, IL-6, ITGB3, MMP-14, and VEGF-A; angiogenesis inhibiting: COL18A1, TIMP-2, and TIMP-3). In conclusion, we observed a protective effect of genistein on skin flap viability which could be potentially applied in plastic surgery to women undergoing a reconstructive and/or plastic intervention. Nevertheless, further research is needed to explain the exact underlying mechanism and to find the optimal treatment protocol.

Indexed as

AnimalsCell SurvivalEndothelial CellsGene Expression ProfilingGene Expression RegulationGenisteinHumansHuman Umbilical Vein Endothelial CellsModels, AnimalProto-Oncogene Proteins c-bcl-2RatsSuperoxide DismutaseSurgical FlapsTime FactorsUp-RegulationGenisteinProto-Oncogene Proteins c-bcl-2Superoxide DismutaseBcl-2CATendothelial cellestrogenflap surgeryischemiaskin repairSODwound healing

Identifiers

PMID29973576
PMCPMC6100613
OpenAlexW2810324377

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.